@article{b8c9b82d075b484983be2e7a89caead8,
title = "Applications of artificial intelligence in prostate cancer histopathology",
abstract = "The diagnosis of prostate cancer (PCa) depends on the evaluation of core needle biopsies by trained pathologists. Artificial intelligence (AI) derived models have been created to address the challenges posed by pathologists{\textquoteright} increasing workload, workforce shortages, and variability in histopathology assessment. These models with histopathological parameters integrated into sophisticated neural networks demonstrate remarkable ability to identify, grade, and predict outcomes for PCa. Though the fully autonomous diagnosis of PCa remains elusive, recently published data suggests that AI has begun to serve as an initial screening tool, an assistant in the form of a real-time interactive interface during histological analysis, and as a second read system to detect false negative diagnoses. Our article aims to describe recent advances and future opportunities for AI in PCa histopathology.",
keywords = "Artificial intelligence, Deep learning, Gleason grading, Histopathology, Machine learning, Prostate cancer",
author = "Dallin Busby and Ralph Grauer and Krunal Pandav and Akshita Khosla and Parag Jain and Mani Menon and Haines, {G. Kenneth} and Carlos Cordon-Cardo and Gorin, {Michael A.} and Tewari, {Ashutosh K.}",
note = "Funding Information: This research did not receive any specific grant from funding agencies in the public, commercial, or not-for-profit sectors. However, the authors wish to acknowledge and disclose funding support for other projects from the Deane Prostate Health, Icahn School of Medicine at Mount Sinai, The Arthur M. Blank Family Foundation, The Kovner Foundation and Lizzie and Jonathan Tisch. Dr. Tewari has served as a site-PI on pharma/industry-sponsored clinical trials from Kite Pharma Inc., Lumicell, Inc., Dendron Pharmaceuticals, LLC, Oncovir Inc., Blue Earth Diagnostics Ltd., RhoVac ApS., Bayer HealthCare Pharmecauticals Inc., Janssen Research and Development, LLC. He has received research funding (grants) to his institution from DOD, NIH, Axogen, Intuitive surgical, AMBF, and other philanthropy. Dr. Tewari has served as an unpaid consultant to Roivant Biosciences and advisor to Promaxo. He owns equity in Promaxo. Publisher Copyright: {\textcopyright} 2022",
year = "2023",
doi = "10.1016/j.urolonc.2022.12.002",
language = "English",
journal = "Urologic Oncology: Seminars and Original Investigations",
issn = "1078-1439",
publisher = "Elsevier Inc.",
}